Novel Interventions for Colorectal Cancer
(CANTOR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests new treatments for colorectal cancer to evaluate their efficacy and safety. Participants are divided into two groups: one receives a combination of three drugs—Volrustomig (experimental treatment), FOLFIRI (chemotherapy regimen), and Bevacizumab (anti-angiogenesis drug)—while the other receives only FOLFIRI and Bevacizumab. The study seeks individuals with colorectal cancer without liver metastasis who have not recently undergone chemotherapy for metastatic cancer. Candidates should feel generally well enough to manage daily activities and have a life expectancy of at least 12 weeks. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in cancer treatment.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that combining Bevacizumab with FOLFIRI (a mix of cancer-fighting drugs) is generally well-tolerated by patients with colorectal cancer. These treatments have been used together before and have improved treatment outcomes.
For the new addition, Volrustomig, studies are ongoing to assess its safety. Since this trial is in the middle phase of testing, Volrustomig has shown promise but is still under careful evaluation to ensure safety.
The goal of combining these treatments is to maximize effectiveness while maintaining safety for participants. Serious side effects have not been specifically reported, but some side effects may occur. Participants should discuss any concerns with the research team.12345Why are researchers excited about this trial's treatments?
Unlike the standard treatment for colorectal cancer, which typically includes chemotherapy regimens like FOLFIRI combined with bevacizumab, the investigational drug Volrustomig adds a new twist by potentially enhancing the effectiveness of these traditional therapies. Researchers are excited about Volrustomig because it introduces a novel mechanism of action that targets specific pathways involved in tumor growth and survival. This innovative approach could lead to improved outcomes by not only slowing down the progression of the cancer but also increasing the overall efficacy of the existing treatment regimen.
What evidence suggests that this trial's treatments could be effective for colorectal cancer?
Research has shown that combining bevacizumab with FOLFIRI (a mix of cancer-fighting drugs) can improve outcomes for people with advanced colorectal cancer. Bevacizumab blocks a protein that tumors need to grow blood vessels, starving the tumors of nutrients. FOLFIRI, which includes irinotecan, 5-FU, and leucovorin, kills cancer cells or stops them from multiplying. In this trial, participants in Arm A will receive volrustomig in addition to this treatment. Volrustomig is still under study but is expected to enhance the treatment's effectiveness. Early results suggest that this combination could outperform the use of just FOLFIRI and bevacizumab, which participants in Arm B will receive.23456
Are You a Good Fit for This Trial?
This trial is for adults with confirmed colorectal cancer, good performance status (able to carry out daily activities), expected to live at least 12 weeks, no liver metastasis, and haven't had systemic therapy for metastatic CRC. They must have a specific tumor type (pMMR/MSS), be over 35 kg in weight, and have measurable disease.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive either Volrustomig + FOLFIRI + bevacizumab or FOLFIRI + bevacizumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- Bevacizumab
- FOLFIRI
- Volrustomig
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Parexel
Industry Sponsor
Peyton Howell
Parexel
Chief Executive Officer
Master of Healthcare Administration from The Ohio State University, Bachelor of Arts in Health Communications from the University of Illinois
Dr. Austin Smith
Parexel
Chief Medical Officer since 2023
MD from the Royal College of Surgeons in Ireland